Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pirlindole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.95 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.95 |
| ▸ | MEN1 | O00255 | 6/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | TP53 | P04637 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.95 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | DRD1 | P21728 | 1/20 | 0.95 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.95 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirlindole SCHEMBL18878061 | 0.97 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL373564 | 0.97 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL18877133 | 0.97 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL29500947 | 0.97 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL4157397 | 0.96 | HSD17B10 (0.97) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL4152460 | 0.91 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL30984462 | 0.90 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL3761340 | 0.90 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL17241165 | 0.81 | HSD17B10 (0.68) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL13702963 | 0.81 | KMT2A (0.98) | HSD17B10MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM1 755/4885SLC6A2 35/4885SLC6A3 44/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM1 648/4885SLC6A2 34/4885SLC6A3 41/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM1 755/4885SLC6A2 35/4885SLC6A3 44/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | CHRM1 755/4885SLC6A2 35/4885SLC6A3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.